search
Back to results

Endoscopic Sleeve Gastroplasty for Morbid Obesity

Primary Purpose

Endoscopic Sleeve Gastroplasty

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Endoscopic Sleeve Gastroplasty
Laparoscopic Sleeve Gastrectomy
Sponsored by
Chinese University of Hong Kong
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Endoscopic Sleeve Gastroplasty

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. A BMI > 35 kg/m2
  2. A BMI > 30 kg/m2 with T2DM
  3. A BMI>3 30kg/m2 with 2 or more co-morbidities

Exclusion Criteria:

  1. Significant anaesthetic risk (> ASA III)
  2. History of diabetic ketoacidosis or hyperosmolar coma
  3. Uncontrolled T2 DM with HbA1c > 12%
  4. A BMI > 45 kg/m2
  5. Malignancy diagnosed within 5 years
  6. Endoscopic findings of any pre-neoplastic/neoplastic lesions, portal hypertensive gastropathy or significant varices
  7. Chronic renal failure requiring dialysis
  8. Previous upper abdominal surgery (including bariatric surgery) affecting gastroduodenal configuration
  9. Major psychiatric illness including major depression and substance abuse
  10. Pregnancy or ongoing breast-feeding
  11. Inmates

Sites / Locations

  • Chinese University of Hong Kong

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Endoscopic Sleeve Gastroplasty

Laparoscopic Sleeve Gastrectomy

Arm Description

A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava[29] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.

Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.

Outcomes

Primary Outcome Measures

Percentage of excess weight loss

Secondary Outcome Measures

operative time
total blood loss intra-operation
total blood loss will be recorded in operation record
early postoperative pain scores
perioperative complications
mortality
postoperative hospital stay
Percentages of excess weight loss
(%EWL)
total weight loss
(%TWL)

Full Information

First Posted
April 19, 2017
Last Updated
April 19, 2017
Sponsor
Chinese University of Hong Kong
search

1. Study Identification

Unique Protocol Identification Number
NCT03124485
Brief Title
Endoscopic Sleeve Gastroplasty for Morbid Obesity
Official Title
Prospective Randomized Trial Comparing Endoscopic Sleeve Gastroplasty Versus Conventional Laparoscopic Sleeve Gastrectomy in Patients With Morbid Obesity: From Physical and Functional Outcomes to Changes in Hormonal Profiles
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Unknown status
Study Start Date
August 2017 (Anticipated)
Primary Completion Date
August 2020 (Anticipated)
Study Completion Date
September 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese University of Hong Kong

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Obesity and its related metabolic disorders are increasingly a heavy health burden to many parts of the world. Weight control is a well-known important step in avoiding type 2 diabetes mellitus (T2DM). It is also an essential component for normalizing the blood glucose and preventing macrovascular and microvascular insults to patients with diagnosed T2DM. However, life-style modification, physical exercise and dietary adjustment are ineffective measures which are unlikely to confer adequate and sustainable weight loss for the truly obese. On the other hand, large scale long-term follow-up studies have confirmed the role of bariatric surgery in providing durable weight loss and remarkable improvement on medical comorbidities. Among all the bariatric operations, laparoscopic sleeve gastrectomy (LSG) is currently the most widely adopted procedure worldwide because of its simplicity and effectiveness in weight reduction. However, LSG is not without risk. Staple-line hemorrhage, leakage and stenosis are potentially life-threatening complications. LSG is also costly because of the need for expensive laparoscopic staplers.
Detailed Description
A new endoscopic bariatric therapy, namely endoscopic sleeve gastroplasty (ESG), has recently been proposed as a non-surgical procedure for the management of obesity with or without diabetes mellitus. Preliminary data based on single arm series or phase II studies have reported promising short and intermediate term weight control effect. However, whether ESG is a feasible option comparable to LSG in the intermediate term remains an unanswered question. In addition, physical and functional outcomes after ESG were not well documented in most of the reported series. Realizing there is a knowledge gap in applying ESG to patients with morbid obesity, we propose to study and compare the efficacy of weight control and functional outcomes of ESG against conventional LSG. Through this prospective randomized trial, the safety profiles, quality of life and changes in fasting and post-prandial gut hormone secretion after the two procedures will also be assessed and compared. The evidence thus generated shall lay a scientific foundation for ESG which may become an alternative choice for patients who have concerns about complication and irreversibility of most bariatric surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endoscopic Sleeve Gastroplasty

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
This study protocol aims to test the hypothesis that endoscopic sleeve gastroplasty (ESG) IS NOT inferior to conventional laparoscopic surgical sleeve gastrectomy (LSG) in terms of weight loss and improvement of glycemic control for Asian obese patients. It also investigates and compares the safety profile, improvement of co-morbidities, functional outcomes and changes in gut hormone profiles between the two bariatric procedures.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
37 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Endoscopic Sleeve Gastroplasty
Arm Type
Experimental
Arm Description
A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava[29] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
Arm Title
Laparoscopic Sleeve Gastrectomy
Arm Type
Active Comparator
Arm Description
Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
Intervention Type
Procedure
Intervention Name(s)
Endoscopic Sleeve Gastroplasty
Intervention Description
An oesophageal overtube is then inserted to facilitate passage of the endoscope mounted with Overstitch device. A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava[29] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic Sleeve Gastrectomy
Intervention Description
Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
Primary Outcome Measure Information:
Title
Percentage of excess weight loss
Time Frame
1 year
Secondary Outcome Measure Information:
Title
operative time
Time Frame
during operation
Title
total blood loss intra-operation
Description
total blood loss will be recorded in operation record
Time Frame
during operation
Title
early postoperative pain scores
Time Frame
7 days
Title
perioperative complications
Description
mortality
Time Frame
30 days
Title
postoperative hospital stay
Time Frame
30 days
Title
Percentages of excess weight loss
Description
(%EWL)
Time Frame
1 year
Title
total weight loss
Description
(%TWL)
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A BMI > 35 kg/m2 A BMI > 30 kg/m2 with T2DM A BMI>3 30kg/m2 with 2 or more co-morbidities Exclusion Criteria: Significant anaesthetic risk (> ASA III) History of diabetic ketoacidosis or hyperosmolar coma Uncontrolled T2 DM with HbA1c > 12% A BMI > 45 kg/m2 Malignancy diagnosed within 5 years Endoscopic findings of any pre-neoplastic/neoplastic lesions, portal hypertensive gastropathy or significant varices Chronic renal failure requiring dialysis Previous upper abdominal surgery (including bariatric surgery) affecting gastroduodenal configuration Major psychiatric illness including major depression and substance abuse Pregnancy or ongoing breast-feeding Inmates
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Candice Lam
Phone
35052956
Email
candicelam@surgery.cuhk.edu.hk
First Name & Middle Initial & Last Name or Official Title & Degree
Jenny Ho
Phone
35052956
Email
jennyho@surgery.cuhk.edu.hk
Facility Information:
Facility Name
Chinese University of Hong Kong
City
Hong Kong
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Endoscopic Sleeve Gastroplasty for Morbid Obesity

We'll reach out to this number within 24 hrs